相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients
Kambiz Rahbar et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
Longterm outcome of peptide receptor radionuclide therapy (PRRT) in 454 patients with progressive neuroendocrine tumors using yttrium-90 and lutetium-177 labelled somatostatin receptor targeting peptides
D. Hörsch et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Symptoms and QOL as Predictors of Chemoprevention Adherence in NRG Oncology/NSABP Trial P-1
Stephanie R. Land et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Symptoms and QOL as Predictors of Chemoprevention Adherence in NRG Oncology/NSABP Trial P-1
Stephanie R. Land et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Translational Diagnostics and Therapeutics in Pancreatic Neuroendocrine Tumors
Jessica E. Maxwell et al.
CLINICAL CANCER RESEARCH (2016)
Nephrotoxicity after PRRT with 177Lu-DOTA-octreotate
Hendrik Bergsma et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2016)
Radiolabeled Somatostatin Analogue Therapy Of Gastroenteropancreatic Cancer
Lisa Bodei et al.
SEMINARS IN NUCLEAR MEDICINE (2016)
Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors
P. Jimenez-Fonseca et al.
CANCER AND METASTASIS REVIEWS (2015)
Neoadjuvant Treatment of Nonfunctioning Pancreatic Neuroendocrine Tumors with [177Lu-DOTA0,Tyr3]Octreotate
Esther I. van Vliet et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
Dose Response of Pancreatic Neuroendocrine Tumors Treated with Peptide Receptor Radionuclide Therapy Using 177Lu-DOTATATE
Ezgi Ilan et al.
JOURNAL OF NUCLEAR MEDICINE (2015)
Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors
Lisa Bodei et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2015)
Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate
Amir Sabet et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2014)
Outcome and toxicity of salvage therapy with 177Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumours
Amir Sabet et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2014)
Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours
Samer Ezziddin et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2014)
Radiopharmaceutical Therapy of Patients with Metastasized Melanoma with the Melanin-Binding Benzamide I-131-BA52
Walter Mier et al.
JOURNAL OF NUCLEAR MEDICINE (2014)
Predictors of Long-Term Outcome in Patients with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy with 177Lu-Octreotate
Samer Ezziddin et al.
JOURNAL OF NUCLEAR MEDICINE (2014)
Can peptide receptor radionuclide therapy be safely applied in florid bone metastases? A pilot analysis of late stage osseous involvement
A. Sabet et al.
NUKLEARMEDIZIN-NUCLEAR MEDICINE (2014)
Determinants and associated factors influencing medication adherence and persistence to oral anticancer drugs: A systematic review
M. Verbrugghe et al.
CANCER TREATMENT REVIEWS (2013)
Peptide-based Radiopharmaceuticals for Targeted Tumor Therapy
C. Dong et al.
CURRENT MEDICINAL CHEMISTRY (2013)
The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours
John J. Zaknun et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2013)
Long-Term Hematotoxicity After Peptide Receptor Radionuclide Therapy with 177Lu-Octreotate
Amir Sabet et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
Peptide receptor radionuclide therapy (PRRT) for GEP-NETs
Hendrik Bergsma et al.
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY (2012)
Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study
Lisa Bodei et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2011)
Response and Long-Term Control of Bone Metastases After Peptide Receptor Radionuclide Therapy with 177Lu-Octreotate
Samer Ezziddin et al.
JOURNAL OF NUCLEAR MEDICINE (2011)
Quality of Life in 265 Patients with Gastroenteropancreatic or Bronchial Neuroendocrine Tumors Treated with [177Lu-DOTA0,Tyr3]Octreotate
Saima Khan et al.
JOURNAL OF NUCLEAR MEDICINE (2011)
The Association of Quality-of-Life Measures With Malignancy and Survival in Patients With Pancreatic Pathology
Vic Velanovich
PANCREAS (2011)
Radioembolization of Liver Tumors With Yttrium-90 Microspheres
Hojjat Ahmadzadehfar et al.
SEMINARS IN NUCLEAR MEDICINE (2010)
Gastroenteropancreatic neuroendocrine tumours
Irvin M. Modlin et al.
LANCET ONCOLOGY (2008)
Neuroendocrine tumors of the gastro-entero-pancreatic system
Sara Massironi et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2008)
Endocrine tumours of the pancreas
K Öberg et al.
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY (2005)
5-Hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomised controlled trial
JT Hickok et al.
LANCET ONCOLOGY (2005)
Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3] octreotate in patients with endocrine gastroenteropancreatic tumors
DJ Kwekkeboom et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3] octreotate
JJM Teunissen et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
分享论文
